The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
Official Title: Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial
Study ID: NCT02391051
Brief Summary: This trial examines the feasibility and toxicity of focal brachytherapy in patients with low-risk prostate cancer.
Detailed Description: Patients with low-risk prostate cancer will receive HDR-Brachytherapy: 2 x 13,5 Gy.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
University Hospital, Erlangen, , Germany
Name: Vratislav Strnad, MD
Affiliation: University Hospital Erlangen, Dept. of Radiooncology
Role: STUDY_CHAIR
Name: Bastian Keck, MD
Affiliation: University Hospital Erlangen, Dept. of Urology
Role: STUDY_CHAIR
Name: Alexander Cavallaro, MD
Affiliation: University Hospital Erlangen, Dept. of Radiology
Role: STUDY_CHAIR
Name: Arndt Hartmann, MD
Affiliation: University Hospital Erlangen, Dept. of Pathology
Role: STUDY_CHAIR
Name: Michael Lotter, Dipl.-Phys.
Affiliation: University Hospital Erlangen, Dept. of Radiooncology
Role: STUDY_CHAIR
Name: Annedore Strnad, MD, MHBA
Affiliation: University Hospital Erlangen, Dept. of Radiooncology
Role: STUDY_CHAIR
Name: Peter Goebell, MD
Affiliation: University Hospital Erlangen, Dept. of Urology
Role: STUDY_CHAIR
Name: Wolfgang Uter, MD
Affiliation: University Erlangen; Dept. of Biometrics and Epidemiology
Role: STUDY_CHAIR
Name: Michael Uder, MD
Affiliation: University Hospital Erlangen, Dept. of Radiology
Role: STUDY_CHAIR
Name: Bernd Wullich, MD
Affiliation: University Hospital Erlangen, Dept. of Urology
Role: STUDY_CHAIR
Name: Rainer Fietkau, MD
Affiliation: University Hospital Erlangen, Dept. of Radiooncology
Role: STUDY_CHAIR